← Back to Screener
Aktis Oncology, Inc. Common stock (AKTS)
Price$18.60
Favorite Metrics
Price vs S&P 500 (26W)-80.97%
Price vs S&P 500 (4W)-6.86%
Market Capitalization$966.06M
All Metrics
P/CF (Annual)65.44x
Book Value / Share (Quarterly)$0.94
P/TBV (Annual)0.80x
Revenue Growth (3Y)147.45%
Price vs S&P 500 (YTD)-20.09%
Gross Margin (TTM)-11.60%
Net Profit Margin (TTM)-226.20%
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-0.95
Revenue Growth (5Y)86.32%
EPS (Annual)$-0.87
ROI (Annual)-17.91%
Gross Margin (Annual)-11.49%
Net Profit Margin (5Y Avg)-443.97%
Cash / Share (Quarterly)$4.86
Revenue Growth QoQ (YoY)735.20%
ROA (Last FY)-13.48%
Revenue Growth TTM (YoY)49.91%
EBITD / Share (TTM)$-0.86
ROE (5Y Avg)-68.61%
Operating Margin (TTM)-244.28%
Cash Flow / Share (Annual)$0.23
P/B Ratio4.81x
P/B Ratio (Quarterly)0.66x
Net Income / Employee (Annual)$-297,691
EPS Growth QoQ (YoY)16.66%
EPS Incl Extra (Annual)$-0.87
Current Ratio (Annual)15.98x
Quick Ratio (Quarterly)9.15x
3-Month Avg Trading Volume0.40M
52-Week Price Return-82.46%
EV / Free Cash Flow (Annual)78.06x
Revenue / Employee (TTM)$128,631
Tangible BV / Share (Quarterly)$0.53
P/S Ratio (Annual)649.67x
Asset Turnover (Annual)0.00x
52-Week High$29.16
Operating Margin (5Y Avg)-431.94%
EPS Excl Extra (Annual)$-0.87
CapEx CAGR (5Y)10.40%
Tangible BV CAGR (5Y)32.95%
26-Week Price Return-79.37%
Quick Ratio (Annual)15.79x
13-Week Price Return-16.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.27x
Enterprise Value$928.904
Revenue / Share Growth (5Y)49.17%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)13.89%
Revenue / Employee (Annual)$127,030
Inventory Turnover (Annual)5.19x
Pretax Margin (Annual)-2957.63%
Cash / Share (Annual)$5.87
3-Month Return Std Dev68.95%
Gross Margin (5Y Avg)-21.94%
Net Income / Employee (TTM)$-290,969
ROE (Last FY)-17.91%
Net Interest Coverage (Annual)-48.09x
EPS Basic Excl Extra (Annual)$-0.87
Receivables Turnover (TTM)8.26x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.95
Receivables Turnover (Annual)6.35x
ROI (TTM)-53.11%
P/S Ratio (TTM)1.58x
Pretax Margin (5Y Avg)-452.15%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.78
Free OCF CAGR (5Y)30.87%
Price vs S&P 500 (52W)-84.50%
EPS Growth TTM (YoY)19.36%
Year-to-Date Return-19.24%
5-Day Price Return2.38%
EPS Normalized (Annual)$-0.87
ROA (5Y Avg)-46.94%
Net Profit Margin (Annual)-2957.63%
Month-to-Date Return1.12%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-1.00
Operating Margin (Annual)-3500.34%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-51.05%
LT Debt / Equity (Quarterly)62.67x
EPS Basic Excl Extra (TTM)$-0.95
P/TBV (Quarterly)1.16x
P/B Ratio (Annual)0.00x
Inventory Turnover (TTM)5.95x
Pretax Margin (TTM)-234.57%
Book Value / Share (Annual)$4.85
Price vs S&P 500 (13W)-17.52%
Beta167.10x
P/FCF (Annual)81.18x
Revenue / Share (TTM)$0.42
ROE (TTM)-47.53%
52-Week Low$14.72
Analyst Recommendations
Mar 2026
Apr 2026
4.30
4.27
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AKTSAktis Oncology, Inc. Common stock | 1.58x | 49.91% | -11.60% | — | $18.60 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Aktis Oncology is a clinical-stage oncology company developing targeted alpha radiopharmaceuticals for solid tumors, including breast, lung, colorectal, bladder, and liver cancers. The company focuses on expanding access to large patient populations not addressed by existing platform technologies. Its pipeline includes AKY-1189 and AKY-2519.